Literature DB >> 19292766

The expression profile of functional regulatory T cells, CD4+CD25high+/forkhead box protein P3+, in patients with ulcerative colitis during active and quiescent disease.

K Kamikozuru1, K Fukunaga, S Hirota, N Hida, Y Ohda, K Yoshida, Y Yokoyama, K Tozawa, K Kawa, M Iimuro, K Nagase, A R Saniabadi, S Nakamura, H Miwa, T Matsumoto.   

Abstract

Regulatory T cells (T(reg)) have an essential role in maintaining immune tolerance in the gut. The functional CD4(+) T(reg) express the transcription factor forkhead box protein 3 (FoxP3) or a CD25(high) in humans. Further, depletion of elevated granulocytes/monocytes by extracorporeal adsorption (GMA) induces immunomodulation in patients with ulcerative colitis (UC). We investigated the impact of GMA on T(reg). Thirty-one UC patients, clinical activity index (CAI) 12.1 +/- 2.97, refractory to conventional medications including intravenous corticosteroid and 13 healthy controls (HC), were included. Patients received five GMA sessions over 5 weeks. Biopsies from the rectal mucosa and blood samples at baseline and post-GMA were immunostained with anti-CD4/FoxP3 and anti-CD4/CD25 antibodies for immunohistochemistry and flow cytometry. Following GMA, 22 of 31 patients achieved remission (CAI <or= 4, P < 0.01) and their endoscopic activity index decreased from 10.6 +/- 2.32 to 4.75 +/- 1.48 (P = 0.003). The circulating CD4(+)CD25(high+) T(reg) level was low and increased markedly in responders (P < 0.02). In the nine non-responders, the baseline CD4(+)CD25(high+) T(reg) level was about 50% of the level in the responders (P < 0.03) or in the HC (P < 0.01), and all nine had to undergo colectomy. Conversely, the number of CD4(+)/FoxP3(+) mucosal T(reg) in GMA responders decreased significantly after the fifth GMA session compared with the baseline level (P < 0.05). It is believed that the CD4(+) T(reg) has an essential role in the control of immune pathology in UC patients and a net influx of these cells from the circulation into the mucosa may proceed to suppress inflammation. GMA can impact the circulating as well as the mucosal levels of T(reg).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19292766      PMCID: PMC2759481          DOI: 10.1111/j.1365-2249.2009.03904.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  28 in total

1.  CD25+ CD4+ T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10.

Authors:  O Annacker; R Pimenta-Araujo; O Burlen-Defranoux; T C Barbosa; A Cumano; A Bandeira
Journal:  J Immunol       Date:  2001-03-01       Impact factor: 5.422

Review 2.  Therapeutic leukocytapheresis for inflammatory bowel disease.

Authors:  Abbi R Saniabadi; Hiroyuki Hanai; Ken Fukunaga; Koji Sawada; Chikako Shima; Ingvar Bjarnason; Robert Lofberg
Journal:  Transfus Apher Sci       Date:  2007-10-31       Impact factor: 1.764

3.  Down-regulation of interferon-gamma parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study.

Authors:  V Muratov; J Lundahl; A K Ulfgren; K Elvin; I Fehrman; N Ahlborg; A Ost; N Hittel; A Saniabadi; R Löfberg
Journal:  Int J Colorectal Dis       Date:  2006-03-15       Impact factor: 2.571

Review 4.  Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis.

Authors:  Hiroyuki Hanai
Journal:  World J Gastroenterol       Date:  2006-12-21       Impact factor: 5.742

Review 5.  Inflammatory bowel diseases: a disease (s) of modern times? Is incidence still increasing?

Authors:  Cristina Saro Gismera; Beatriz Sicilia Aladrén
Journal:  World J Gastroenterol       Date:  2008-09-28       Impact factor: 5.742

6.  Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study.

Authors:  T Shimoyama; K Sawada; N Hiwatashi; T Sawada; K Matsueda; A Munakata; H Asakura; T Tanaka; R Kasukawa; K Kimura; Y Suzuki; Y Nagamachi; T Muto; H Nagawa; B Iizuka ; S Baba; M Nasu; T Kataoka; N Kashiwagi; A R Saniabadi
Journal:  J Clin Apher       Date:  2001       Impact factor: 2.821

7.  Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells.

Authors:  C A Piccirillo; E M Shevach
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

8.  Demonstration of low-regulatory CD25High+CD4+ and high-pro-inflammatory CD28-CD4+ T-Cell subsets in patients with ulcerative colitis: modified by selective granulocyte and monocyte adsorption apheresis.

Authors:  Yoko Yokoyama; Ken Fukunaga; Yoshihiro Fukuda; Katsuyuki Tozawa; Koji Kamikozuru; Kunio Ohnishi; Takeshi Kusaka; Tadashi Kosaka; Nobuyuki Hida; Yoshio Ohda; Hiroto Miwa; Takayuki Matsumoto
Journal:  Dig Dis Sci       Date:  2007-04-03       Impact factor: 3.199

9.  Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease.

Authors:  Jochen Maul; Christoph Loddenkemper; Pamela Mundt; Erika Berg; Thomas Giese; Andreas Stallmach; Martin Zeitz; Rainer Duchmann
Journal:  Gastroenterology       Date:  2005-06       Impact factor: 22.682

10.  Basal lymphoid aggregates in ulcerative colitis colon: a site for regulatory T cell action.

Authors:  B Sitohy; S Hammarström; A Danielsson; M-L Hammarström
Journal:  Clin Exp Immunol       Date:  2008-02       Impact factor: 4.330

View more
  11 in total

1.  Infliximab therapy impacts the peripheral immune system of immunomodulator and corticosteroid naïve patients with Crohn's disease.

Authors:  Kyoichi Kato; Ken Fukunaga; Koji Kamikozuru; Shinichiro Kashiwamura; Nobuyuki Hida; Yoshio Ohda; Naohisa Takeda; Koji Yoshida; Masaki Iimuro; Yoko Yokoyama; Risa Kikuyama; Hiroto Miwa; Takayuki Matsumoto
Journal:  Gut Liver       Date:  2011-03-16       Impact factor: 4.519

Review 2.  Extracorporeal photopheresis as a therapy for autoimmune diseases.

Authors:  Zoya Kuzmina; David Stroncek; Steven Z Pavletic
Journal:  J Clin Apher       Date:  2014-12-26       Impact factor: 2.821

3.  Mass Cytometry and Single-Cell Transcriptome Analyses Reveal the Immune Cell Characteristics of Ulcerative Colitis.

Authors:  Yongxin Luo; Shiying Liu; Huibiao Li; Jiangtao Hou; Wenjia Lin; Zewen Xu; Tianyu Lu; Yanwu Li; Bin Peng; Shijing Zhang; Xue Han; Zuoliang Kuang; Yi Wen; Jiazhong Cai; Fengbin Liu; Xin-Lin Chen
Journal:  Front Mol Biosci       Date:  2022-06-23

4.  Therapeutic granulocyte and monocyte apheresis (GMA) for treatment refractory sarcoidosis: a pilot study of clinical effects and possible mechanisms of action.

Authors:  H H Olsen; V Muratov; K Cederlund; J Lundahl; A Eklund; J Grunewald
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

Review 5.  Cellular mediators of inflammation: tregs and TH17 cells in gastrointestinal diseases.

Authors:  Franco Pandolfi; Rossella Cianci; Danilo Pagliari; Raffaele Landolfi; Giovanni Cammarota
Journal:  Mediators Inflamm       Date:  2010-02-08       Impact factor: 4.711

6.  Immunological ignorance allows long-term gene expression after perinatal recombinant adeno-associated virus-mediated gene transfer to murine airways.

Authors:  Marianne S Carlon; Dragana Vidović; James Dooley; Marina Mori da Cunha; Michael Maris; Youlia Lampi; Jaan Toelen; Chris Van den Haute; Veerle Baekelandt; Jan Deprest; Erik Verbeken; Adrian Liston; Rik Gijsbers; Zeger Debyser
Journal:  Hum Gene Ther       Date:  2014-03-26       Impact factor: 5.695

Review 7.  Disrupted regulatory T cell homeostasis in inflammatory bowel diseases.

Authors:  Christophe Pedros; Fanny Duguet; Abdelhadi Saoudi; Marianne Chabod
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

8.  Effect of two recombinant Trichinella spiralis serine protease inhibitors on TNBS-induced experimental colitis of mice.

Authors:  J Xu; L Wu; P Yu; M Liu; Y Lu
Journal:  Clin Exp Immunol       Date:  2018-09-23       Impact factor: 4.330

Review 9.  Selective granulocyte and monocyte apheresis in inflammatory bowel disease: Its past, present and future.

Authors:  Xiu-Li Chen; Jing-Wei Mao; Ying-De Wang
Journal:  World J Gastrointest Pathophysiol       Date:  2020-05-12

Review 10.  Apheresis: A cell-based therapeutic tool for the inflammatory bowel disease.

Authors:  Farah Yasmin; Hala Najeeb; Unaiza Naeem; Abdul Moeed; Thoyaja Koritala; Salim Surani
Journal:  World J Clin Cases       Date:  2022-07-26       Impact factor: 1.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.